Why the study?
How do pharmacologic interventions and valvular heart disease influence left ventricular ejection phase indices measured by echocardiography?
How do pharmacologic interventions and valvular heart disease influence left ventricular ejection phase indices measured by echocardiography?
Echocardiographic ejection phase indices are sensitive to pharmacologic interventions but have limited clinical value in assessing true LV function in the presence of left-sided volume overload conditions like mitral or aortic regurgitation.
Caution against relying on normal ejection phase indices in regurgitation; leaves open prospective validation of circumferential indices.
Echocardiography represents an established noninvasive technique to evaluate left ventricular (LV) performance. The LV ejection phase indices may be divided into three categories: (1) volume-dependent, (2) circumferential, and (3) wall thickening. Since the latter two are not volume dependent, they are clinically more useful in patients with dilated left ventricles. These parameters have limited clinical value in the presence of left-sided volume overload conditions (e g, mitral regurgitation and aortic regurgitation) since significant LV dysfunction may exist in the presence of normal ejection phase indices by echo. The echocardiogram is also a sensitive procedure to detect subtle alterations in LV function following acute or chronic interventions with various types of vasoactive and inotropic drugs.
No takes yet. Share an insight, caveat, or question.
Arthur D. Hagan (1979) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: